Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Drugs
Published in: Pediatric Drugs 5/2017

01-10-2017 | Review Article

Treatment of Juvenile Dermatomyositis: An Update

Authors: Charalampia Papadopoulou, Lucy R. Wedderburn

Published in: Pediatric Drugs | Issue 5/2017

Login to get access

Abstract

The idiopathic inflammatory myopathies of childhood consist of a heterogeneous group of autoimmune diseases characterised by proximal muscle weakness and pathognomonic skin rashes. The overall prognosis of juvenile myositis has improved significantly over recent years, but the long-term outcome differs substantially from patient to patient, suggestive of distinct clinical phenotypes with variable responses to treatment. High doses of corticosteroids remain the cornerstone of therapy along with other immunosuppressant therapies depending on disease severity and response. The advent of biological drugs has revolutionised the management of various paediatric rheumatologic diseases, including inflammatory myopathies. There are few data from randomised controlled trials to guide management decisions; thus, several algorithms for the treatment of juvenile myositis have been developed using international expert opinion. The general treatment goals now include elimination of active disease and normalisation of physical function, so as to preserve normal growth and development, and to prevent long-term damage and deformities. This review summarises the newer and possible future therapies of juvenile inflammatory myopathies, including evidence supporting their efficacy and safety.
Literature
1.
Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol. 2009;23(5):665–78.PubMedPubMedCentralCrossRef
2.
McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 yr. Rheumatol (Oxford). 2006;45(10):1255–60.CrossRef
3.
Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin N Am. 2002;28(4):833–57.CrossRef
4.
Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthr Care Res. 2010;62(1):63–72.CrossRef
5.
Tansley SL, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthr Res Ther. 2013;15(2):211.CrossRef
6.
Tansley S, Wedderburn LR. Comparing and contrasting clinical and serological features of juvenile and adult-onset myositis: implications for pathogenesis and outcomes. Curr Opin Rheumatol. 2015;27(6):601–7.PubMedCrossRef
7.
Bitnum S, Daeschner CW Jr, Travis LB, Dodge WF, Hopps HC. Dermatomyositis. J Pediatr. 1964;64:101–31.PubMedCrossRef
8.
9.
Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthr Rheum. 2000;43(3):541–9.CrossRef
10.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.PubMedCrossRef
11.
Whitaker JN, Engel WK. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N Engl J Med. 1972;286(7):333–8.PubMedCrossRef
12.
Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13(1–2):59–68.PubMedPubMedCentral
13.
Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthr Rheum. 1982;25(2):126–39.CrossRef
14.
Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol. 1990;27(4):343–56.PubMedCrossRef
15.
Page G, Chevrel G, Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells. Arthr Rheum. 2004;50(1):199–208.CrossRef
16.
Suarez-Calvet X, Gallardo E, Nogales-Gadea G, Querol L, Navas M, Diaz-Manera J, et al. Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis. J Pathol. 2014;233(3):258–68.PubMedCrossRef
17.
18.
Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthr Rheum. 2009;60(11):3425–35.CrossRef
19.
Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine. 1991;70(6):360–74.PubMedCrossRef
20.
Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol. 2007;19(6):523–9.PubMedCrossRef
21.
Wedderburn LR, McHugh NJ, Chinoy H, Cooper RG, Salway F, Ollier WE, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatol (Oxford). 2007;46(12):1786–91.CrossRef
22.
Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis. 2009;68(10):1621–5.PubMedCrossRef
23.
Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthr Rheum. 2009;60(6):1807–14.CrossRef
24.
Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, et al. Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis. Arthr Rheumatol. 2016;68(11):2806–16.CrossRef
25.
Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631):2201–12.PubMedCrossRef
26.
Lowry CA, Pilkington CA. Juvenile dermatomyositis: extramuscular manifestations and their management. Curr Opin Rheumatol. 2009;21(6):575–80.PubMedCrossRef
27.
Dugan EM, Huber AM, Miller FW, Rider LG, International Myositis Assessment and Clinical Studies Group. Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J. 2009;15(2):2.PubMed
28.
Schmeling H, Stephens S, Goia C, Manlhiot C, Schneider R, Luthra S, et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. Rheumatol (Oxford). 2011;50(5):885–93.CrossRef
29.
Tse S, Lubelsky S, Gordon M, Al Mayouf SM, Babyn PS, Laxer RM, et al. The arthritis of inflammatory childhood myositis syndromes. J Rheumatol. 2001;28(1):192–7.PubMed
30.
Schwartz T, Sanner H, Husebye T, Flato B, Sjaastad I. Cardiac dysfunction in juvenile dermatomyositis: a case–control study. Ann Rheum Dis. 2011;70(5):766–71.PubMedCrossRef
31.
Schwartz T, Sanner H, Gjesdal O, Flato B, Sjaastad I. In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity. Ann Rheum Dis. 2014;73(10):1805–10.PubMedCrossRef
32.
Sallum AM, Pivato FC, Doria-Filho U, Aikawa NE, Liphaus BL, Marie SK, et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr. 2008;84(1):68–74.CrossRef
33.
Pope E, Janson A, Khambalia A, Feldman B. Childhood acquired lipodystrophy: a retrospective study. J Am Acad Dermatol. 2006;55(6):947–50.PubMedCrossRef
34.
Brown VE, Pilkington CA, Feldman BM, Davidson JE. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatol (Oxford). 2006;45(8):990–3.CrossRef
35.
Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthr Rheum. 2004;50(7):2281–90.CrossRef
36.
Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthr Rheum. 2008;59(1):4–13.CrossRef
37.
McCann LJ, Kirkham JJ, Wedderburn LR, Pilkington C, Huber AM, Ravelli A, et al. Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. Trials. 2015;12(16):268.CrossRef
38.
Kim S, Kahn P, Robinson AB, Lang B, Shulman A, Oberle EJ, et al. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol Online J. 2017;15(1):1.PubMedPubMedCentralCrossRef
39.
Huber AM, Kim S, Reed AM, Carrasco R, Feldman BM, Hong SD, et al. Childhood Arthritis and Rheumatology Research Alliance Consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. J Rheumatol. 2017;44(1):110–6.PubMedCrossRef
40.
Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329–40.PubMedCrossRef
41.
Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol. 2010;37(9):1953–61.PubMedCrossRef
42.
Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47(4):505–11.PubMedCrossRef
43.
Seshadri R, Feldman BM, Ilowite N, Cawkwell G, Pachman LM. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthr Rheum. 2008;59(7):989–95.CrossRef
44.
Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin N Am. 1997;23(3):619–55.CrossRef
45.
Rider LG, Miller FW, Targoff IN, Sherry DD, Samayoa E, Lindahl M, et al. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthr Rheum. 1994;37(10):1534–8.CrossRef
46.
Romicka AM. Use of intravenous megadoses of methylprednisolone for treatment of dermatomyositis in children. Pediatria Polska. 1995;70(3):243–8.PubMed
47.
Klein-Gitelman MS, Waters T, Pachman LM. The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthr Care Res Off J Arthr Health Prof Assoc. 2000;13(6):360–8.
48.
Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthr Rheum. 2008;59(2):222–6.CrossRef
49.
Byron MA, Jackson J, Ansell BM. Effect of different corticosteroid regimens on hypothalamic-pituitary-adrenal axis and growth in juvenile chronic arthritis. J R Soc Med. 1983;76(6):452–7.PubMedPubMedCentral
50.
Binns E, Maillard S, Tansley S, McHugh NJ, Wedderburn LR, Pilkington C, et al. Effective induction therapy for anti-SRP associated myositis in childhood; three case reports and a review of the literature (under review).
51.
52.
Miller LC, Sisson BA, Tucker LB, DeNardo BA, Schaller JG. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthr Rheum. 1992;35(10):1143–9.CrossRef
53.
Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthr Rheum. 2005;52(11):3570–8.CrossRef
54.
Jacobs JC. Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics. 1977;59(2):212–8.PubMed
55.
Niakan E, Pitner SE, Whitaker JN, Bertorini TE. Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis. Neurology. 1980;30(3):286–91.PubMedCrossRef
56.
Fischer TJ, Rachelefsky GS, Klein RB, Paulus HE, Stiehm ER. Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone. Am J Dis Child. 1979;133(4):386–9.PubMedCrossRef
57.
Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–8.PubMedCrossRef
58.
Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N, et al. Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol. 2011;29(1):117–24.PubMed
59.
Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthr Rheum. 2004;50(7):2191–201.CrossRef
60.
61.
Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol. 2004;31(1):179–82.PubMed
62.
van der Meer A, Wulffraat NM, Prakken BJ, Gijsbers B, Rademaker CM, Sinnema G. Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol. 2007;25(3):480–5.PubMed
63.
Bulatovic M, Heijstek MW, Verkaaik M, van Dijkhuizen EH, Armbrust W, Hoppenreijs EP, et al. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthr Rheum. 2011;63(7):2007–13.CrossRef
64.
Ortiz-Alvarez O, Morishita K, Avery G, Green J, Petty RE, Tucker LB, et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol. 2004;31(12):2501–6.PubMed
65.
Ravelli A, Migliavacca D, Viola S, Ruperto N, Pistorio A, Martini A. Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol. 1999;17(5):625–7.PubMed
66.
Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol. 1997;24(12):2436–43.PubMed
67.
Pistoia V, Buoncompagni A, Scribanis R, Fasce L, Alpigiani G, Cordone G, et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis–dermatomyositis. Results of a preliminary study. Clin Exp Rheumatol. 1993;11(2):203–8.PubMed
68.
Heckmatt J, Hasson N, Saunders C, Thompson N, Peters AM, Cambridge G, et al. Cyclosporin in juvenile dermatomyositis. Lancet. 1989;1(8646):1063–6.PubMedCrossRef
69.
Fasano S, Alves SC, Isenberg DA. Current pharmacological treatment of idiopathic inflammatory myopathies. Exp Rev Clin Pharmacol. 2016;06:1–12.
70.
Dzudie A, Boissonnat P, Roussoulieres A, Cakmak Mosbah K, Bejui FT, et al. Cyclosporine-related posterior reversible encephalopathy syndrome after heart transplantation: should we withdraw or reduce cyclosporine? Case reports. Transplant Proc. 2009;41(2):716–20.PubMedCrossRef
71.
Cosottini M, Lazzarotti G, Ceravolo R, Michelassi MC, Canapicchi R, Murri L. Cyclosporine-related posterior reversible encephalopathy syndrome (PRES) in non-transplant patient: a case report and literature review. Eur J Neurol. 2003;10(4):461–2.PubMedCrossRef
72.
Kawasumi H, Gono T, Kawaguchi Y, Yamanaka H. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl 1):9–17.PubMedPubMedCentral
73.
Dagher R, Desjonqueres M, Duquesne A, Quartier P, Bader-Meunier B, Fischbach M, et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int. 2012;32(3):711–6.PubMedCrossRef
74.
Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthr Care Res. 2010;62(10):1446–51.CrossRef
75.
76.
77.
Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatol (Oxford). 2004;43(4):491–6.CrossRef
78.
Brunner HI, Silva CA, Reiff A, Higgins GC, Imundo L, Williams CB, et al. Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. Arthr Rheumatol. 2015;67(5):1377–85.CrossRef
79.
Deakin C, Campanilho-Marques R, Simou S, Moraitis E, Pullenayegum E, Wedderburn L, et al. Analysis of efficacy and safety of cyclophosphamide in juvenile dermatomyositis using a large national UK cohort [abstract]. Arthr Rheumatol. 2016;68(suppl 10):1–4550.
80.
Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol. 1989;16(12):1545–7.PubMed
81.
Sterba Y, Wahezi D. Cross-sectional evaluation of hydroxychloroquine (HCQ) therapy in children with juvenile dermatomyositis (JDM) enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. 2014 ACR/ARHP annual meeting 2014.
82.
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. American Academy of Ophthalmology recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386–94.PubMedCrossRef
83.
Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol. 2008;27(11):1469–71.PubMedCrossRef
84.
Huber AM. Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment. Paediatr Drugs. 2009;11(6):361–74.PubMedCrossRef
85.
86.
Collet E, Dalac S, Maerens B, Courtois JM, Izac M, Lambert D. Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol. 1994;130(2):231–4.PubMedCrossRef
87.
Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol. 2000;27(10):2498–503.PubMed
88.
Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med. 1991;91(2):169–72.PubMedCrossRef
89.
Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis. 2011;70(12):2089–94.PubMedCrossRef
90.
Levy DM, Bingham CA, Kahn PJ, Eichenfield AH, Imundo LF. Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids. J Pediatr. 2010;156(2):302–7.PubMedCrossRef
91.
Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthr Care Res. 2012;64(4):546–53.CrossRef
92.
Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med. 1986;314(9):560–4.PubMedCrossRef
93.
Ferreira A, Garcia Rodriguez MC, Lopez-Trascasa M, Pascual Salcedo D, Fontan G. Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with gamma-globulin. Clin Immunol Immunopathol. 1988;47(2):199–207.PubMedCrossRef
94.
Horn J, Thon V, Bartonkova D, Salzer U, Warnatz K, Schlesier M, et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol. 2007;122(2):156–62.PubMedCrossRef
95.
Palabrica FR, Kwong SL, Padua FR. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study. Asia Pac Allergy. 2013;3(4):249–56.PubMedPubMedCentralCrossRef
96.
Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29(3):173–84.PubMedCrossRef
97.
Beresford MW, Baildam EM. New advances in the management of juvenile idiopathic arthritis—2: the era of biologicals. Arch Dis Child Educ Pract Ed. 2009;94(5):151–6.PubMedCrossRef
98.
Sen ES, Ramanan AV. New age of biological therapies in paediatric rheumatology. Arch Dis Child. 2014;99(7):679–85.PubMedCrossRef
99.
100.
Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2:CD008794.
101.
Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol. 2014;10(10):612–27.PubMedCrossRef
102.
Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38(7):1436–40.PubMedCrossRef
103.
Chiu YE, Co DO. Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. Pediatr Dermatol. 2011;28(4):357–67.PubMedCrossRef
104.
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthr Rheum. 2013;65(2):314–24.CrossRef
105.
Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthr Rheumatol. 2014;66(3):740–9.CrossRef
106.
Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthr Care Res. 2010;62(9):1328–34.CrossRef
107.
108.
Salmon JH, Cacoub P, Combe B, Sibilia J, Pallot-Prades B, Fain O, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015;1(1):e000034.PubMedPubMedCentralCrossRef
109.
Efthimiou P. Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications. Semin Arthr Rheum. 2006;36(3):168–72.CrossRef
110.
Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatol (Oxford). 2008;47(6):877–80.CrossRef
111.
Campanilho-Marques R, Deakin C, Simou S, Wedderburn L, Pilkington C. Efficacy and safety of tumour necrosis factor antagonists in a large cohort of juvenile dermatomyositis patients [abstract]. Ann Rheum Dis. 2016;75(Suppl2):140.
112.
Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67(12):1670–7.PubMedCrossRef
113.
Brunasso AM, Aberer W, Massone C. New onset of dermatomyositis/polymyositis during anti-TNF-alpha therapies: a systematic literature review. Sci World J. 2014;2014:179180.CrossRef
114.
Cantaert T, Baeten D, Tak PP, van Baarsen LG. Type I IFN and TNFalpha cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. Arthr Res Ther. 2010;12(5):219.CrossRef
115.
Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9(9):806–15.PubMedPubMedCentralCrossRef
116.
Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, Schroeder S, Lauener R, Saurenmann RK. Infliximab in pediatric rheumatology patients: a retrospective analysis of infusion reactions and severe adverse events during 2246 infusions over 12 years. J Rheumatol. 2014;41(7):1409–15.PubMedCrossRef
117.
Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthr Rheumatol. 2014;66(9):2580–9.CrossRef
118.
Kondo M, Murakawa Y, Matsumura T, Matsumoto O, Taira M, Moriyama M, et al. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatol (Oxford). 2014;53(10):1907–8.CrossRef
119.
Cabrera N, Duquesne A, Desjonqueres M, Larbre JP, Lega JC, Fabien N, et al. Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children. RMD Open. 2016;2(2):e000271.PubMedPubMedCentralCrossRef
120.
Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatol (Oxford). 2011;50(7):1344–6.CrossRef
121.
Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Joint Bone Spine Revue du Rhumatisme. 2011;78(4):431–2.CrossRef
122.
Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr. 2012;160(3):520–2.PubMedPubMedCentralCrossRef
123.
Kerola AM, Kauppi MJ. Abatacept as a successful therapy for myositis—a case-based review. Clin Rheumatol. 2015;34(3):609–12.PubMedCrossRef
124.
Vojinovic J, Cimaz R. Vitamin D-update for the pediatric rheumatologists. Pediatr Rheumatol Online J. 2015;29(13):18.CrossRef
125.
Soybilgic A, Tesher M, Wagner-Weiner L, Onel KB. A survey of steroid-related osteoporosis diagnosis, prevention and treatment practices of pediatric rheumatologists in North America. Pediatr Rheumatol Online J. 2014;12:24.PubMedPubMedCentralCrossRef
126.
Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open. 2014;4(5):e004587.PubMedPubMedCentralCrossRef
127.
Takken T, van der Net J, Helders PJ. Anaerobic exercise capacity in patients with juvenile-onset idiopathic inflammatory myopathies. Arthr Rheum. 2005;53(2):173–7.CrossRef
128.
Butbul Aviel Y, Stremler R, Benseler SM, Cameron B, Laxer RM, Ota S, et al. Sleep and fatigue and the relationship to pain, disease activity and quality of life in juvenile idiopathic arthritis and juvenile dermatomyositis. Rheumatol (Oxford). 2011;50(11):2051–60.CrossRef
129.
Maillard SM, Jones R, Owens CM, Pilkington C, Woo PM, Wedderburn LR, et al. Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthr Rheum. 2005;53(4):558–64.CrossRef
130.
Habers EA, van Brussel M, Langbroek-Amersfoort AC, van Royen-Kerkhof A, Takken T. Design of the muscles in motion study: a randomized controlled trial to evaluate the efficacy and feasibility of an individually tailored home-based exercise training program for children and adolescents with juvenile dermatomyositis. BMC Musculoskelet Disord. 2012;21(13):108.CrossRef
131.
Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthr Rheum. 2009;60(11):3436–46.CrossRef
132.
Reed AM, Peterson E, Bilgic H, Ytterberg SR, Amin S, Hein MS, et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthr Rheum. 2012;64(12):4078–86.CrossRef
133.
Liu Y, Ramot Y, Torrelo A, Paller AS, Si N, Babay S, et al. Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthr Rheum. 2012;64(3):895–907.CrossRef
Metadata
Title
Treatment of Juvenile Dermatomyositis: An Update
Authors
Charalampia Papadopoulou
Lucy R. Wedderburn
Publication date
01-10-2017
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 5/2017
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-017-0240-6

Other articles of this Issue 5/2017

Pediatric Drugs 5/2017 Go to the issue

Review Article

Pharmacotherapy for Pediatric Neurogenic Bladder

Current Opinion

Clinical Trial Design in Juvenile Idiopathic Arthritis

Original Research Article

Understanding the Stability of Dopamine and Dobutamine Over 24 h in Simulated Neonatal Ward Conditions

Leading Article

A Review of the Safety, Efficacy and Mechanisms of Delivery of Nasal Oxytocin in Children: Therapeutic Potential for Autism and Prader-Willi Syndrome, and Recommendations for Future Research

Original Research Article

Alternating Acetaminophen and Ibuprofen versus Monotherapies in Improvements of Distress and Reducing Refractory Fever in Febrile Children: A Randomized Controlled Trial

Review Article

Clinical Management of Dystonia in Childhood